FDA OK's Impax's long-awaited Parkinson's drug Rytary
This article was originally published in Scrip
Executive Summary
The FDA on 8 January finally gave its blessing to Impax Pharmaceuticals to market its Parkinson's disease drug Rytary, an extended-release oral capsule formulation of carbidopa-levodopa.
You may also be interested in...
Amneal’s IPX-203 Increases ‘Good’ ON Time For Parkinson’s Patients
The proprietary carbidopa/levodopa formulation increased good ON time with fewer doses versus immediate-release levodopa. A post-hoc analysis also showed 1.55 hours more ON time per dose.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.